| Primary information |
|---|
| sequence ID | Seq_1208 |
| Peptide sequence | DEAGSEADHEGTHSTKRGHAKSRPV |
| CancerPDF_ID | CancerPDF_ID21, CancerPDF_ID1037, CancerPDF_ID1259, CancerPDF_ID3764, CancerPDF_ID8536, CancerPDF_ID8612, CancerPDF_ID9933, CancerPDF_ID10623, CancerPDF_ID11086, CancerPDF_ID12724, |
| PMID | 16896061,16395409,21136997,27026199,23667664,26705257,21124649,21805675,26482227,27058005 |
| Protein Name | Fibrinogen alpha chain,Fibrinogen alpha chain,Fibrinogen alpha,Fibrinogen alpha chain,Fibrinogen alpha,Isoform 2 of fibrinogen (FGA) chain precursor,Fibrinogen alpha chain,Fibrinogen alpha chain,FIBA_HUMAN,Fibrinogen alpha chain |
| UniprotKB Entry Name | FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN |
| Fluid | Serum,Serum,Serum,Urine,Serum,Serum,Serum,Urine,Urine,Serum |
| M/Z | 2659.03,2659.03,2658.24947,NA,2658.25,2660.11,NA,2659.2521,2660.82,2659.323 |
| Charge | 1,1,1,NA,1,NA,NA,NA,NA,NA |
| Mass (in Da) | 2659.24,NA,NA,NA,2660.78,NA,NA,NA,NA,NA |
| fdr | NA,NA,NA,2658.25,NA,NA,2659.8,NA,NA,NA |
| Profiling Technique | MALDI-TOF,MALDI-TOF,LC-MS,"CE-MS, Micro-TOF-MS",MALDI-TOF,MALDI-TOF,LC-MS,MALDI-TOF,MALDI-TOF,MALDI-TOF |
| Peptide Identification technique | Q/TOF MS/MS,Q/TOF/TOF and LC-MS/MS,LC-MS-MS/MS,MS-MS,FT-ICR MS/MS + nano-HPLC,LC-ESI-MS/MS,LC-ESI-MS/MS,MALDI-TOF-MS,LC-ESI-MS/MS,LC-MS/MS |
| Quantification Technique | NA,NA,LC-ESI-MS,NA,NA,NA,NA,NA,NA,NA |
| Labelled/Label Free | Label Free,Label Free,Label Free,Label Free,Label Free,Label Free,Labelled,Label Free,Label Free,Label Free |
| FDR | NA,less than 1 “5,NA,NA,NA,NA,NA,1,FDR less than 5 %,NA |
| CancerPDF_ID | CancerPDF_ID21, CancerPDF_ID1037, CancerPDF_ID1259, CancerPDF_ID3764, CancerPDF_ID8536, CancerPDF_ID8612, CancerPDF_ID9933, CancerPDF_ID10623, CancerPDF_ID11086, CancerPDF_ID12724, |
| p-Value | 1.00E-05,3.78E-08,NA,less than 0.01,NA,1.00E-06,7.39E-12,NA,NA,"less than 0.05,0.229,0.693" |
| Software | MASCOT,MASCOT (v 2.0.04 for Windows),MASCOT(v. 2.2.01),Proteome Discoverer 1.2,MASCOT,ClinProTools,NA,NA,MASCOT,Proteome Discoverer |
| Length | 25,25,25,25,25,25,25,25,NA,25 |
| Cancer Type | Metastatic thyroid carcinomas,"Advanced Prostate, Breast and Bladder cancer",Colorectal cancer,Bladder cancer,"Breast cancer, Lung cancer, Rectal cancer",Breast cancer,Breast cancer,Muscle-invasive bladder cancer,Clear cell renal carcinoma,Breast cancer |
| Database | NCBI refseq Protein Database,NCBI refseq Protein Database,SwissProt Database,Uniprot Human non-redundant Database,NA,Uniprot protein sequence Database,NCBI Protein Database,SwissProt Database,SwissProt Database,SwissProt Database |
| Modification | NA,NA,NA,NA,NA,NA,NA,NA,NA,NA |
| Number of Patients | 40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,"Advanced prostate (n = 32), breast (n = 21), and bladder (n = 20) cancer, 33 healthy",30 patients and 30 healthy controls, 425 for training(109 patients with Recurrent UBC cases and 316 negative for recurrence controls) and 211 for validation (55 UBC recurrent cases and 156 recurrent controls),"Breast Cancer =84, lung cancer= 70, Rectal cancer = 30patients; 500 healthy",96 Breast Cancer patients and 64 healthy controls,9 BC and 9 control,751 bladder cancer and 127 control,"117 clear cell RCC patients (ccRCC) (72 men, 45 women)"," 28 were diagnosed with Breast cancer, 27 remained cancer-free with BRCA carrier. Of the remaining patients, 39 were diagnosed with sporadic breast cancer (SBC), and 38 were healthy volunteers (WT)." |
| Regulation | NA,"Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) = 1.37, 1.18 and 2.45 in prostate, bladder and breast cancer respectively",NA,Differentially expressed between recurrence of UBC vs recurrence control,NA,Upregulated in cancer as compare to normal control with fold change of 1.5,Differentially expressed between cancer vs control,Differentially expressed between cancer vs normal samples,Upregulated with increse in tumor mass,"Upregulated with the fold change of 0.73 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.88, Upregulated in BC vs healthy with 1.033 fold change" |
| Validation | Independent validation,Independent validation,Leave One out Cross validation,Independent Validation,NA,NA,NA,Mann-Whitney tests and areas under receiver-operator characteristic,external cross validation not done,NA |
| Sensitivity | 95% on independent dataset,97.5% on independent validation dataset,NA,For testing dataset 88%,NA,0.7904,NA,NA,NA,NA |
| Specificity | 95% on independent dataset,NA,NA,For testing dataset 51%,NA,82.18,NA,NA,NA,NA |
| Accuracy | NA,97.5 % on validation dataset,NA,NA,NA,NA,NA,NA,NA,NA |
| Peptide Atlas | NA |
| IEDB | |